Roche Holding AG: Final Decision From European Commission On Ocrevus Approval Expected Soon
Ocrevus Reduced Risk Of Relapses By 48% Compared With Fingolimod In Paediatric MS
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.